Skip to main content Skip to search Skip to main navigation

EDQM: Ph. Eur. Pre-Publishes Cannabis Flower Monograph

The new monograph on Cannabis flower (3028) will be published in Ph. Eur. Supplement 11.5 in January 2024. Given the exceptionally high interest from stakeholders in having access to the new text as soon as possible, the Ph. Eur. decided to make the monograph immediately available on the EDQM website for information.

The new text covers the herbal drug defined as the dried, whole or fragmented, fully developed female inflorescences of Cannabis sativa L. It is to be read in conjunction with the general monograph Herbal drugs (1433), which includes additional requirements that are applicable unless otherwise stated in the Cannabis flower monograph.

The new monograph takes into account information received from a number of national authorities concerning the use of the herbal drug in their jurisdictions: it can be employed as a raw material for the production of extracts or it can be prescribed as is, to be taken by patients by inhalation or oral administration. Additional requirements have been included in the limits for content, in the production section and in the tests for foreign matter, arsenic, cadmium and lead for cases in which the herbal drug is to be prescribed to patients.

The EDQM will hold a webinar on 14 December 2023 (15:30 – 17:00 CET) to present the new monograph to its stakeholders to help them prepare for implementation of the text as of 1 July 2024. You can register here.


Source:

EDQM Newsroom

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
Previous
Next